You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Systematic Medical Approach to Reward Transformation SMART for Brain Health in Opioid Use Disorder

    SBC: Versa Integrated Solutions, Inc.            Topic: 102

    Summary In recent years opioid use disorder OUD and deaths due to opiate overdose e g with heroin fentanyl oxycodone in suburban and rural non minority groups has created an urgency for approaches to stem this epidemic but the rise in OUD and opiate overdose deaths has occurred in inner cities at similar rates Heroin misuse and addiction are persistent problems in African American commu ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Recombinant High Affinity Long and Dual Acting Equine CG Analogs for Improved and More Ethical Reproduction in Pigs and Cattle

    SBC: TROPHOGEN INC            Topic: NICHD

    As their first application for veterinary health the two PI s have already remarkably employed their novel patented superagonist and neoglycosylation technology to develop the first recombinant much more potent and long acting bovine FSH antagonists for improved cattle reproduction and a potential $ Million annual market This work was supported by a previous phase SBIR from FDA CVM whic ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Therapies for Duchenne Muscular Dystrophy

    SBC: MYOLOGICA, LLC            Topic: NIAMS

    Project Summary Myologica is a small business focused on developing therapeutics for neuromuscular diseases Started in collaboration with the University of Maryland Myologica maintains a vigorous in house pre clinical discovery program in Duchenne Muscular Dystrophy DMD while providing consultation and specialized neuromuscular function testing for non profit and corporate clients The object ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Development and Commercialization of Predictive Biomarker Panel and In Office Kit for the Management of Diabetic Macular Edema

    SBC: OCULAR PROTEOMICS, LLC            Topic: N

    Abstract Diabetic Macular Edema DME is a vision threatening stage in Diabetic Retinopathy DR that can result in legal blindness The biochemical mechanisms that drive DME progression are not well understood and treatments address only portions of the disease pathology The available treatment options vary widely from injectable anti VEGF to injectable steroids to laser treatments and carry a ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Novel Plasma Based Microsatellite Instability Diagnostic for Guiding Immunotherapy

    SBC: Personal Genome Diagnostics Inc.            Topic: 102

    Abstract Immune checkpoint inhibitors have recently emerged as a revolution in cancer care providing the potential for durable response and improved survival for numerous cancer patients across multiple cancer types However only of patients who are treated with checkpoint inhibitors have responded in most cancer types necessitating biomarker assays that can reliably and accurately ident ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a companion diagnostic to predict response to cetuximab in patients with head and neck squamous cell carcinoma

    SBC: Biomarker Strategies, LLC            Topic: 100

    ABSTRACT Head and neck squamous cell carcinoma HNSCC is the world s th leading cause of cancer accounting for of cancer mortality For many other cancers molecular characterization has led to sub classification of disease based on the status of oncogenic drivers in signal transduction pathways leading to the development of molecularly targeted agents MTAs targeting specific dysregulate ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel Targeted Nanomedicine Delivering MicroRNA-30-5p ReplacementTherapy for Multi-drug Resistant Cancer Treatment

    SBC: MIRECULE INC            Topic: NCI

    AbstractIn this SBIR application miRecule proposes to develop a microRNA based therapeutic mimic of miRpmiRecule candidate MCfor the treatment of multi drug resistantMDRcancersHead and Neck Squamous Cell CarcinomaHNSCCis theth most common form of cancerGreater than half of patients present with late stage III or IV diseasewith an averageyear survival rate ofHNSCC tumors have high levels of genetic ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Development of biopsy devices for improved preservation of multiple biopsy tissue samples

    SBC: ROBIN MEDICAL INC            Topic: 113

    Project Summary Molecular medicine holds promise for advancing medical diagnosis and treatment if biomarkers can be accurately assessed in tissues for example in tumors The long term objective of the project is to bring to market new tools for better biopsy tissue acquisition processing and storing A first new biopsy device aims to acquire multiple samples into a cartridge and to stabilize the ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Polyionic Papillomavirus like Particles VLP for the Treatment of HPV oropharyngeal squamous cell carcinomas OPCs

    SBC: PATHOVAX LLC            Topic: 102

    The broader impact commercial potential of PathoVax s STTR phase I proposal is to improve outcomes of cancer immuno therapy utilizing a vaccine formulation combining an immunogenic chimeric virus like particle cVLP vaccine with FDA approved immune check point inhibitors PathoVax proposes to develop this technology for treatment of human papillomavirus HPV associated cancers However cancer ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a novel Virus Like Particle vaccine based cancer immunotherapy targeting PD L

    SBC: VLP THERAPEUTICS, INC.            Topic: 102

    Abstract Cancer immunotherapy has revolutionized today s treatments for many forms of cancers In particular blocking antibodies to immune checkpoint proteins such as programmed cell death PD and its ligand programmed cell death ligand PD L effectively unleash immune cell destruction of cancerous cells However the high cost of these antibody based immunotherapies their intensive ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government